These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 19877264

  • 21. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.
    Liver Transpl; 2005 Jan; 11(1):61-7. PubMed ID: 15690537
    [Abstract] [Full Text] [Related]

  • 22. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z, Wałaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, Kokot F, Klinger M, Szenohradsky P, Studenik P, Navratil P, Asztalos L, Rutkowski B, Nagy KK, Hickey D.
    Ann Transplant; 2002 Jan; 7(3):28-31. PubMed ID: 12465429
    [Abstract] [Full Text] [Related]

  • 23. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation.
    Reggiani P, Arru M, Regazzi M, Gatti S, Molinaro MD, Caccamo L, Maggi U, Melada E, Paone G, Rossi G.
    Transplant Proc; 2005 May; 37(4):1697-9. PubMed ID: 15919435
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J.
    Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
    [Abstract] [Full Text] [Related]

  • 26. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation.
    Ciancio G, Gaynor JJ, Roth D, Kupin W, Hanson L, Tueros L, Zarak A, Ruiz P, Burke GW.
    Transplant Proc; 2010 Nov; 42(9):3503-6. PubMed ID: 21094804
    [Abstract] [Full Text] [Related]

  • 27. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
    Pascual J, van Hooff JP, Salmela K, Lang P, Rigotti P, Budde K.
    Transplantation; 2006 Jul 15; 82(1):55-61. PubMed ID: 16861942
    [Abstract] [Full Text] [Related]

  • 28. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL, Wang D, Wu WZ, Lin WH, Xu TZ, Cai JQ, Tan JM.
    Transpl Immunol; 2008 Jan 15; 18(3):281-5. PubMed ID: 18047938
    [Abstract] [Full Text] [Related]

  • 29. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report.
    Jain AB, Hamad I, Rakela J, Dodson F, Kramer D, Demetris J, McMichael J, Starzl TE, Fung JJ.
    Transplantation; 1998 Nov 27; 66(10):1395-8. PubMed ID: 9846530
    [Abstract] [Full Text] [Related]

  • 30. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients.
    Silverstein DM, Aviles DH, LeBlanc PM, Jung FF, Vehaskari VM.
    Pediatr Transplant; 2005 Oct 27; 9(5):589-97. PubMed ID: 16176415
    [Abstract] [Full Text] [Related]

  • 31. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ, Yang HC, Holman MJ, Ahsan N.
    J Transpl Coord; 1999 Jun 27; 9(2):114-8. PubMed ID: 10703393
    [Abstract] [Full Text] [Related]

  • 32. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation.
    Guethoff S, Meiser BM, Groetzner J, Eifert S, Grinninger C, Ueberfuhr P, Reichart B, Hagl C, Kaczmarek I.
    Transplantation; 2013 Feb 27; 95(4):629-34. PubMed ID: 23423270
    [Abstract] [Full Text] [Related]

  • 33. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May 27; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 34. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.
    Clin J Am Soc Nephrol; 2012 Mar 27; 7(3):504-12. PubMed ID: 22282478
    [Abstract] [Full Text] [Related]

  • 35. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, Inomata Y, Isaji S, Tsumura H, Teramukai S, Matsubara Y, Sakabayashi S, Uemoto S.
    Liver Transpl; 2013 Aug 27; 19(8):896-906. PubMed ID: 23696054
    [Abstract] [Full Text] [Related]

  • 36. Alemtuzumab induction in non-hepatitis C positive liver transplant recipients.
    Levitsky J, Thudi K, Ison MG, Wang E, Abecassis M.
    Liver Transpl; 2011 Jan 27; 17(1):32-7. PubMed ID: 21254342
    [Abstract] [Full Text] [Related]

  • 37. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Bergougnoux L, Touchard G.
    Nephrol Dial Transplant; 2008 Jun 27; 23(6):2024-32. PubMed ID: 18199693
    [Abstract] [Full Text] [Related]

  • 38. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report.
    Jain A, Kashyap R, Dodson F, Kramer D, Hamad I, Khan A, Eghestad B, Starzl TE, Fung JJ.
    Transplantation; 2001 Sep 27; 72(6):1091-7. PubMed ID: 11579306
    [Abstract] [Full Text] [Related]

  • 39. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
    Miura M, Harada H, Fukuzawa N, Iwami D, Taniguchi A, Seki T, Togashi M, Ogawa Y, Satoh H, Hirano T.
    Clin Transplant; 2005 Sep 27; 19 Suppl 14():54-8. PubMed ID: 15955170
    [Abstract] [Full Text] [Related]

  • 40. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
    Squifflet JP, Bäckman L, Claesson K, Dietl KH, Ekberg H, Forsythe JL, Kunzendorf U, Heemann U, Land W, Morales JM, Mühlbacher F, Talbot D, Taube D, Tyden G, van Hooff J, Schleibner S, Vanrenterghem Y, European Tacrolimus-MMF Renal Study Group.
    Transplantation; 2001 Jul 15; 72(1):63-9. PubMed ID: 11468536
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.